Title Page
Abstract
Contents
Introduction 9
Materials and Methods 11
Results 17
Discussion 22
Conclusion 29
References 30
국문초록 50
Table 1. Baseline characteristics 37
Table 2. Number of missing data at baseline and during the follow-up period 38
Table 3. Linear mixed-effects models for changes in MDS-UPDRS part 3 scores 39
Table 4. Linear mixed-effects models for changes in MoCA scores 40
Table 5. Interactions between the APOE ε4 allele and time on secondary outcomes 41
Table 6. Results of the Cox regression analyses for predictors of freezing of gait 42
Table 7. Interactions between the APOE ε4 allele and time on longitudinal DAT imaging, CSF, and peripheral blood biomarker changes 43
Figure 1. Associations between the APOE ε4 allele and longitudinal MDS-UPDRS part 3 (A) and MoCA (B) score changes 44
Figure 2. Associations between the APOE ε4 allele and secondary outcomes 45
Figure 3. Kaplan-Meier estimates showing the cumulative risk of FOG in APOE ε4 carriers and non-carriers 46
Figure 4. Associations between the APOE ε4 allele and baseline DAT imaging, CSF, and peripheral blood biomarker levels 47
Figure 5. Associations between the APOE ε4 allele and longitudinal DAT imaging, CSF, and peripheral blood biomarker changes 48